HeartSciences Net Income 2022-2025 | HSCS
HeartSciences net income from 2022 to 2025. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
|
HeartSciences Annual Net Income (Millions of US $) |
|
|---|---|
| 2025 | $-9 |
| 2024 | $-7 |
| 2023 | $-6 |
| 2022 | $-5 |
| 2021 | $-2 |
|
HeartSciences Quarterly Net Income (Millions of US $) |
|
|---|---|
| 2025-07-31 | $-2 |
| 2025-04-30 | $-2 |
| 2025-01-31 | $-3 |
| 2024-10-31 | $-2 |
| 2024-07-31 | $-2 |
| 2024-04-30 | $-2 |
| 2024-01-31 | $-2 |
| 2023-10-31 | $-2 |
| 2023-07-31 | $-1 |
| 2023-04-30 | $-2 |
| 2023-01-31 | $-1 |
| 2022-10-31 | $-2 |
| 2022-07-31 | $-2 |
| 2022-04-30 | $-2 |
| 2022-01-31 | $-1 |
| 2021-10-31 | $-1 |
| 2021-07-31 | $-1 |
| 2021-04-30 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $0.008B | $0.000B |
| Heart Test Laboratories, Inc. d/b/a HeartSciences is a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to expand and improve an ECG's clinical utility. Millions of ECGs are performed every week and the Company's objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. HeartSciences has one of the largest libraries of AI-ECG algorithms and is developing AI-ECG solutions to be made available on either a hardware agnostic cloud-based platform or its proprietary MyoVista? wavECG(TM) device, to help identify cardiovascular disease in any care setting worldwide in a manner to best suit different care providers. HeartSciences' first product candidate for FDA clearance, the MyoVista? wavECG(TM), or the MyoVista(R), is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Veeva Systems (VEEV) | United States | $49.025B | 59.82 |
| Tempus AI (TEM) | United States | $12.432B | 0.00 |
| Doximity (DOCS) | United States | $9.874B | 40.87 |
| Hims & Hers Health (HIMS) | United States | $9.049B | 73.61 |
| IRhythm Technologies (IRTC) | United States | $5.681B | 0.00 |
| Hinge Health (HNGE) | United States | $3.475B | 0.00 |
| Privia Health (PRVA) | United States | $2.991B | 187.08 |
| Heartflow (HTFL) | United States | $2.850B | 0.00 |
| Inspire Medical Systems (INSP) | United States | $2.632B | 43.55 |
| 10x Genomics (TXG) | United States | $2.065B | 0.00 |
| Enovis (ENOV) | United States | $1.802B | 9.46 |
| Omnicell (OMCL) | United States | $1.665B | 34.05 |
| Azenta (AZTA) | United States | $1.405B | 61.32 |
| Phreesia (PHR) | United States | $1.363B | 0.00 |
| Schrodinger (SDGR) | United States | $1.347B | 0.00 |
| Clover Health Investments (CLOV) | United States | $1.307B | 0.00 |
| Claritev (CTEV) | United States | $0.943B | 0.00 |
| Fulgent Genetics (FLGT) | United States | $0.877B | 0.00 |
| Butterfly Network (BFLY) | United States | $0.621B | 0.00 |
| Evolent Health (EVH) | United States | $0.592B | 0.00 |
| Talkspace (TALK) | United States | $0.585B | 117.67 |
| Veradigm (MDRX) | United States | $0.523B | 0.00 |
| Standard BioTools (LAB) | United States | $0.458B | 0.00 |
| Zepp Health (ZEPP) | Netherlands | $0.381B | 0.00 |
| Carlsmed (CARL) | United States | $0.324B | 0.00 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.312B | 0.00 |
| TruBridge (TBRG) | United States | $0.293B | 13.45 |
| CapsoVision (CV) | United States | $0.255B | 0.00 |
| Insight Molecular Diagnostics (IMDX) | United States | $0.216B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.210B | 0.00 |
| Nyxoah SA (NYXH) | Belgium | $0.192B | 0.00 |
| Health Catalyst (HCAT) | United States | $0.190B | 0.00 |
| KORU Medical Systems (KRMD) | United States | $0.172B | 0.00 |
| CareCloud (CCLD) | United States | $0.140B | 7.70 |
| EUDA Health Holdings (EUDA) | Singapore | $0.116B | 0.00 |
| Outset Medical (OM) | United States | $0.113B | 0.00 |
| Pulmonx (LUNG) | United States | $0.085B | 0.00 |
| NetraMark Holdings (AINMF) | Canada | $0.075B | 0.00 |
| American Well (AMWL) | United States | $0.063B | 0.00 |
| HeartBeam (BEAT) | United States | $0.059B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.054B | 0.00 |
| Evaxion - (EVAX) | Denmark | $0.038B | 0.00 |
| 111 (YI) | China | $0.035B | 0.00 |
| Precipio (PRPO) | United States | $0.033B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.028B | 0.00 |
| Lunai Bioworks (LNAI) | United States | $0.020B | 0.00 |
| Zhongchao (ZCMD) | China | $0.018B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.016B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.011B | 0.00 |
| Movano (MOVE) | United States | $0.011B | 0.00 |
| Strata Skin Sciences (SSKN) | United States | $0.009B | 0.00 |
| PROFUSA (PFSA) | United States | $0.008B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.002B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.002B | 0.00 |
| MSP Recovery (MSPR) | United States | $0.001B | 0.00 |